December 2018- Volume 14, Issue 12

In this Issue

Contract Services

Diamond Pharma named best specialist CRO

Diamond Pharma named best specialist CRO

Business award granted at OBN in recognition of expert services in cell and gene therapy

CROs lead industry-wide shift to modernize trial processes

CROs lead industry-wide shift to modernize trial processes

Roughly nine of 10 CROs are taking steps to unify clinical operations for better visibility and improved study execution

Advancing biomarker discovery and therapeutic development

Advancing biomarker discovery and therapeutic development

Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research

Business & Government Policy

Partners in immuno-oncology

Partners in immuno-oncology

MorphoSys and I-Mab sign strategic agreement for novel immuno-oncology agent MOR210

An acquisition and a contract in infectious disease

An acquisition and a contract in infectious disease

Sobi to acquire Synagis rights from AstraZeneca for RSV; Tulane awarded NIH contract for whooping cough

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

The long and short reads of it

The long and short reads of it

Illumina aims at a more comprehensive sequencing offering with the acquisition of PacBio

Clinical Trials

New combo therapy for pancreatic cancer?

New combo therapy for pancreatic cancer?

Pairing investigational peptide with Keytruda yields promising results for BioLineRx

Attacking alopecia areata

Attacking alopecia areata

Concert reveals results for drug to counter autoimmune attack against hair follicles

LOXL2 inhibitor combats fibrosis

LOXL2 inhibitor combats fibrosis

Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound

Positive data for brain cancer treatment

Positive data for brain cancer treatment

Ziopharm provides update on Controlled IL-12 platform at Society for Neuro-Oncology meeting

Against atrial fibrillation

Against atrial fibrillation

GENETIC-AF Phase 2B AFB results presented at AHA 2018 meeting

Diagnostics

Myriad makes strides in companion diagnostics

Myriad makes strides in companion diagnostics

Company announces results for ovarian cancer and an approval for breast cancer

Digging in deep for diagnostics

Digging in deep for diagnostics

Companies continue efforts to develop tests for early Alzheimer’s diagnosis

Testing the waters in genetic screening

Testing the waters in genetic screening

Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, fragile X and Dup15q syndromes

ThyGenX and ThyraMIR data show positive results

ThyGenX and ThyraMIR data show positive results

Interpace Diagnostics presents favorable new study findings at the 88th Annual Meeting of the American Thyroid Association

Discovery

Heal thyself—with a little boost

Heal thyself—with a little boost

Sitryx and Sygnature join hands to develop therapeutics in immuno-oncology and immuno-inflammation

Targeting tumors with TRPV6

Targeting tumors with TRPV6

Drug candidate minimizes cancer cell growth with minimal side effects

Going after Parkinson’s disease with iPS cells

Going after Parkinson’s disease with iPS cells

Keio University and Eisai open path to new techniques for developing neurological therapeutics

Novel approaches to obesity and metabolic disease

Novel approaches to obesity and metabolic disease

Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk

The two faces of AMPK

The two faces of AMPK

Salk scientists unravel how enzyme long thought to suppress cancer may sometimes help tumors survive

Research & Development

Fast, open and free analysis with BioJupies

Fast, open and free analysis with BioJupies

Mount Sinai researchers develop tool that analyzes biomedical data within minutes

Understanding Zika’s methods

Understanding Zika’s methods

New lab technique helps reveal how Zika virus manipulates the immune system by stripping immune cells of their identity

A challenge for Alzheimer’s innovation

A challenge for Alzheimer’s innovation

Business leader fuels global, multimillion-dollar Oskar Fischer Project

Preclinical

Negating nicotine

Negating nicotine

Scripps scientists test enzyme to reduce dependence

Heralding HERA-CD27L

Heralding HERA-CD27L

Preclinical efficacy data of Apogenix compound published in Frontiers in Oncology

Preventing heart disease in cancer survivors

Preventing heart disease in cancer survivors

CDK2 protein said to play critical role in heart damage caused by doxorubicin, a common chemotherapy drug

Innovate looking for answers about NASH

Innovate looking for answers about NASH

Company studies the effects of larazotide on nonalcoholic fatty liver disease

Feature

Commentary

Publishers’ commentary: A year in review and a year’s preview

Publishers’ commentary: A year in review and a year’s preview

The publishers of DDNews check in with their annual look back and look forward for readers of the magazine and visitors of our websites

Transparency vs. opacity

Transparency vs. opacity

The will to understand vs. the will to obscure is not a new theme, but when blended with electronic communications it is given new intensity

Guest Commentary: A more reproducible approach to creating functional Th17 cells

Guest Commentary: A more reproducible approach to creating functional Th17 cells

A look at the importance of Th17 cells for drug discovery and look at how the use of specialized methods to confirm cellular identity provides a level of validation that has not previously been available
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2023 Magazine Front Cover

Latest Issue  

• Volume 19 • Issue 3 • March 2023

March 2023

March 2023 Issue